UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 804

Sortiert nach

PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies

Annals of oncology, 2014-01, Vol.25 (1), p.32-40

2014

Volltextzugriff (PDF)

Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004)

Annals of oncology, 2012-10, Vol.23 (10), p.2619-2626

2012

Volltextzugriff (PDF)

A phase II study of weekly neoadjuvant chemotherapy followed by radical chemoradiation for locally advanced cervical cancer

British journal of cancer, 2013-06, Vol.108 (12), p.2464-2469

2013

Volltextzugriff (PDF)

PARP inhibitors in ovarian cancer

Annals of oncology, 2016-04, Vol.27 Suppl 1 (suppl_1), p.i40-i44

Ledermann, J A

2016

Volltextzugriff (PDF)

A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer

Annals of oncology, 2014-10, Vol.25 (10), p.1988-1995

2014

Volltextzugriff (PDF)

Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data

Annals of oncology, 2013-12, Vol.24 (12), p.3028-3034

2013

Volltextzugriff (PDF)

Updated treatment recommendations for newly diagnosed epithelial ovarian carcinoma from the ESMO Clinical Practice Guidelines

Annals of oncology, 2021-10, Vol.32 (10), p.1300-1303

2021

Volltextzugriff (PDF)

Combining conventional therapy with immunotherapy: A risky business?

European journal of cancer (1990), 2019-05, Vol.113, p.41-44

2019

Volltextzugriff (PDF)

Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments

Annals of oncology, 2015-10, Vol.26 (10), p.2034-2043

2015

Volltextzugriff (PDF)

Tumour- and treatment-related colostomy rates following mitomycin C or cisplatin chemoradiation with or without maintenance chemotherapy in squamous cell carcinoma of the anus in the ACT II trial

Annals of oncology, 2014-08, Vol.25 (8), p.1616-1622

2014

Volltextzugriff (PDF)

Latest clinical evidence and further development of PARP inhibitors in ovarian cancer

Annals of oncology, 2018-06, Vol.29 (6), p.1366-1376

2018

Volltextzugriff (PDF)

Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Annals of oncology, 2022-09, Vol.33 (9), p.860-877

2022

Volltextzugriff (PDF)

Front-line therapy of advanced ovarian cancer: new approaches

Annals of oncology, 2017-11, Vol.28 (suppl_8), p.viii46-viii50

Ledermann, J A

2017

Volltextzugriff (PDF)

Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Annals of oncology, 2013-10, Vol.24 Suppl 6, p.vi24-vi32

2013

Volltextzugriff (PDF)

ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer

Annals of oncology, 2020-12, Vol.31 (12), p.1606-1622

2020

Volltextzugriff (PDF)

Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer

British journal of cancer, 2011-09, Vol.105 (7), p.884-889

2011

Volltextzugriff (PDF)

Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study

Annals of oncology, 2019-07, Vol.30 (7), p.1080-1087

2019

Volltextzugriff (PDF)

A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer

Annals of oncology, 2013-04, Vol.24 (4), p.937-943

2013

Volltextzugriff (PDF)

Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline

Annals of oncology, 2023-01, Vol.34 (1), p.33-47

2023

Volltextzugriff (PDF)

Enhanced repair of DNA interstrand crosslinking in ovarian cancer cells from patients following treatment with platinum-based chemotherapy

British journal of cancer, 2007-10, Vol.97 (7), p.927-933

2007

Volltextzugriff (PDF)

The systemic treatment of recurrent ovarian cancer revisited

Annals of oncology, 2021-06, Vol.32 (6), p.710-725

2021

Volltextzugriff (PDF)

Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial

The Lancet (British edition), 2003-02, Vol.361 (9356), p.457-464

2003

Volltextzugriff (PDF)

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial

The Lancet (British edition), 2003-06, Vol.361 (9375), p.2099-2106

2003

Volltextzugriff (PDF)

Optimal first-line treatment in ovarian cancer

Annals of oncology, 2012-09, Vol.23 Suppl 10, p.x118-x127

2012

Volltextzugriff (PDF)

Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Annals of oncology, 2023-10, Vol.34 (10), p.833-848

2023

Volltextzugriff (PDF)

1 – 25 von 804

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(619)
Mit Volltextzugriff
(718)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(296)
Life Sciences & Biomedicine
(266)
Humans
(253)
Female
(180)
Oncology
(141)
Biological And Medical Sciences
(110)
Medical Sciences
(101)
Middle Aged
(98)
Male
(95)
Ovarian Cancer
(92)
Adult
(86)
Aged
(85)
Ovarian Neoplasms - Drug Therapy
(61)
Chemotherapy
(58)
Tumors
(58)
Animals
(46)
Pharmacology. Drug Treatments
(46)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(39)
Antineoplastic Agents
(38)
Obstetrics & Gynecology
(36)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Annals Of Oncology
(82)
Population
(72)
Journal Of Clinical Oncology
(44)
International Journal Of Gynecological Cancer
(36)
British Journal Of Cancer
(31)
Revue D'histoire De La Pharmacie
(20)
Journal Of Hepatology
(18)
European Journal Of Cancer
(16)
Gynecologic Oncology
(16)
The Lancet
(16)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies

Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004)

A phase II study of weekly neoadjuvant chemotherapy followed by radical chemoradiation for locally advanced cervical cancer

PARP inhibitors in ovarian cancer

A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer

Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data

Updated treatment recommendations for newly diagnosed epithelial ovarian carcinoma from the ESMO Clinical Practice Guidelines

Combining conventional therapy with immunotherapy: A risky business?

Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments

Tumour- and treatment-related colostomy rates following mitomycin C or cisplatin chemoradiation with or without maintenance chemotherapy in squamous cell carcinoma of the anus in the ACT II trial

Latest clinical evidence and further development of PARP inhibitors in ovarian cancer

Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Front-line therapy of advanced ovarian cancer: new approaches

Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer

Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer

Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study

A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer

Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline

Enhanced repair of DNA interstrand crosslinking in ovarian cancer cells from patients following treatment with platinum-based chemotherapy

The systemic treatment of recurrent ovarian cancer revisited

Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial

Optimal first-line treatment in ovarian cancer

Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Suchergebnisse filtern